Physician

Ajit Singh Sawhney, M.D.

According to 2025 Medicare claims, Ajit Sawhney, M.D. (NPI: 1114014438) practices nephrology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is BALBOA NEPHROLOGY MEDICAL GROUP, INC. (NPI: 1316997505; TIN: 952848091) and primary practice location at 92708-7511.

Sawhney's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 126 traditional Medicare patients, billed 494 HCPCS/CPT codes, and received $42,027 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,666 prescription claims across 222 beneficiaries totaling $292,188 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 61 claims. Open Payments data shows 1 records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $198,489 to $42,027. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $960,284 to $292,188. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	301	1,411	$198,489
2016	308	1,254	$161,892
2017	258	1,402	$172,031
2018	250	1,071	$145,428
2019	196	763	$107,149
2020	161	650	$74,489
2021	151	563	$88,352
2022	154	539	$68,420
2023	140	492	$64,911
2024	126	494	$42,027

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	2,251	$960,284
2016	285	2,544	$1,102,488
2017	312	2,963	$1,022,230
2018	353	2,829	$704,950
2019	317	2,292	$589,989
2020	258	1,834	$425,604
2021	228	1,854	$409,432
2022	206	1,553	$363,027
2023	212	1,767	$396,264
2024	222	1,666	$292,188

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	168	$6,539
2016	N/R	168	$6,360
2017	N/R	94	$4,516
2018	N/R	55	$3,033
2019	N/R	N/R	N/R
2020	N/R	57	$835
2021	N/R	90	$23,156
2022	N/R	107	$19,906
2023	N/R	89	$10,738
2024	N/R	61	$6,112

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	12	58	$294
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	19	19	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	94	177	$83
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	25	29	$68
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	100	198	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	55	2,714	$48,764
Veltassa	Patiromer Calcium Sorbitex	18	780	$42,621
Jardiance	Empagliflozin	23	1,890	$37,890
Tradjenta	Linagliptin	43	1,890	$31,915
Rayaldee	Calcifediol	13	390	$9,280

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7527	Everolimus, oral, 0.25 mg	N	N/R	12	$5,556
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	21	$263
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	12	$10

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$29,788	ExThera Medical Corporation

Explore More Providers

FAQ

What Medicare data is available for Ajit Singh Sawhney, M.D.?

Tedicare shows public-source Medicare data for Ajit Singh Sawhney, M.D. (NPI 1114014438), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajit Singh Sawhney, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ajit Singh Sawhney, M.D.?

Ajit Singh Sawhney, M.D. is linked to BALBOA NEPHROLOGY MEDICAL GROUP, INC. (billing NPI 1316997505) in the available physician profile data.

Does Ajit Singh Sawhney, M.D. have Open Payments data?

Ajit Singh Sawhney, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.